The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail vetinfo@hpra.ie


CANIXIN DHPPi lyophilisate and solvent for suspension for injection for dogs

0 cell culture infective dose 50 Lyophilisate and solvent for suspension for injection

Virbac S.A.VPA10988/101/001

Main Information

Trade NameCANIXIN DHPPi lyophilisate and solvent for suspension for injection for dogs
Active SubstancesCanine distemper virus (lederle strain)
Canine parvovirus (cpv 780916 strain)
Canine adenovirus type 2 (manhattan strain)
Canine parainfluenza (manhattan strain)
Strength0 cell culture infective dose 50
Dosage FormLyophilisate and solvent for suspension for injection
Licence HolderVirbac S.A.
Licence NumberVPA10988/101/001

Group Information

ATC CodeQI07AD04 canine distemper virus + canine adenovirus + canine parvovirus + canine parainfluenza virus
Therapeutic ClassImmunological - Live Vaccine
SpeciesDogs

Status

Authorised/WithdrawnAuthorised
Licence Issued16/09/2016
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
« Back